ERBB2 and breast carcinoma: Meanwhile, in a significant proportion of breast cancers, there is overexpression or amplification of tyrosine kinase receptors such as epidermal growth factor receptor (EGFR) and HER2, leading to increased activation of the phosphoinositide 3-kinases (PI3K) pathway [73].